Pascal Prigent, Genfit CEO
After selling failed NASH drug to Ipsen, French startup nabs a liver disease player in small buyout
About two years after Genfit recorded a company-altering flop in NASH, the French biotech’s new vision appears to be coming into sharper focus. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
